| Literature DB >> 28382784 |
Lili Gao1,2, Ben Ma1,3, Li Zhou1,3, Yu Wang1,3, Shuwen Yang1,3, Ning Qu1,3, Yi Gao1,4, Qinghai Ji1,3.
Abstract
The incidence of PTMC has been increasing in the recent years. This study aimed to investigate the diagnostic value of US-FNA in thyroid nodules ≤1 cm and whether the presence of Hashimoto's thyroiditis (HT) in thyroid could influence the accuracy. The patients who accepted US-FNA at FUSCC from December 2012 to November 2015 and followed our criteria were enrolled in this study. We extracted the cytological, pathological, and follow-up US/US-FNA data of patients with subcentimeter nodules. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), false-negative rate (FNR), false-positive rate (FPR), and AUC were calculated to define FNA diagnostic performance in patients. The association of HT with cytological results was analyzed in univariate and multivariate logistic regression analysis. In total, 754 patients with 817 subcentimeter nodules were collected to comprise the FUSCC cohort. Of the 817 nodules, the cytological results were ND/UNS in 80 nodules (9.8%), benign in 74 (9.1%), AUS/FLUS in 80 (9.8%), FN/SFN in 6 (0.7%), suspicious for malignancy (SM) in 222 (27.2%), and malignant in 355 (43.5%). The sensitivity, specificity, PPV, NPV, and AUC of US-FNA for the subcentimeter nodules were 98.8%, 90.5%, 98.8%, 90.5%, and 94.7%, respectively. In comparison with HT-positive subcentimeter nodules, the diagnostic value of US-FNA for HT-negative nodules was significantly higher (HT-positive: AUC = 91.6%, HT-negative: AUC = 95.9%, P = 0.028). The coexistent HT was found to increase the risk of the FNR and indeterminate cytological results. US-FNA demonstrated an effective method for diagnosis of subcentimeter thyroid nodules with a low nondiagnostic rate in our study. The presence of HT in thyroid could be a risk factor for the increased FNR and indeterminate cytological results during US-FNA.Entities:
Keywords: zzm321990FNAzzm321990; Hashimoto's thyroiditis; subcentimeter nodules; thyroid cancer
Mesh:
Year: 2017 PMID: 28382784 PMCID: PMC5430084 DOI: 10.1002/cam4.997
Source DB: PubMed Journal: Cancer Med ISSN: 2045-7634 Impact factor: 4.452
Figure 1The flow graph of inclusion and analysis of study subjects in our study.
Clinicopathological characteristics, US features, and cytological results of patients with subcentimeter nodules in our study
| Variables | ND/UNS | Benign | AUS/FLUS | FN/SFN | SM | Malignant | Total |
|---|---|---|---|---|---|---|---|
| Gender | |||||||
| Female | 64 (9.7%) | 62 (9.4%) | 69 (10.4%) | 5 (0.8%) | 175 (26.4%) | 287 (43.3%) | 662 |
| Male | 16 (10.3%) | 12 (7.7%) | 11 (7.1%) | 1 (0.65) | 47 (30.3%) | 68 (43.9%) | 155 |
| Age (years) | 48.71 ± 12.34 | 49.92 ± 9.85 | 46.65 ± 11.85 | 53.33 ± 15.85 | 46.62 ± 11.30 | 44.51 ± 11.29 | 46.26 ± 11.49 |
| US features | |||||||
| Nodule size (cm) | |||||||
| <0.5 | 11 (7.3%) | 3 (2.0%) | 16 (10.6%) | 1 (0.7%) | 55 (36.4%) | 65 (43.0%) | 151 |
| ≥0.5 | 69 (10.4%) | 71 (10.7%) | 64 (9.6%) | 5 (0.8%) | 167 (25.1%) | 290 (43.5%) | 666 |
| Echogenicity | |||||||
| Hypoechogenicity | 78 (9.8%) | 65 (8.2%) | 79 (9.9%) | 6 (0.8%) | 215 (27.1%) | 351 (44.2%) | 794 |
| Isoechogenicity | 2 (8.7%) | 9 (39.1%) | 1 (4.3%) | 0 (0.0%) | 7 (30.4%) | 4 (17.4%) | 23 |
| Calcification | |||||||
| None | 34 (9.4%) | 37 (10.2%) | 33 (9.1%) | 4 (1.1%) | 94 (26.0%) | 160 (44.2%) | 362 |
| Microcalcification | 32 (9.4%) | 27 (7.9%) | 30 (8.8%) | 2 (0.6%) | 94 (27.6%) | 156 (45.7%) | 341 |
| Macrocalcification | 14 (12.3) | 10 (8.8%) | 17 (14.9%) | 0 (0.0%) | 34 (29.8%) | 39 (34.2%) | 114 |
| Intranodular vascularity | |||||||
| No | 70 (10.3%) | 61 (9.0%) | 64 (9.5%) | 4 (0.6%) | 182 (26.9%) | 296 (43.7%) | 677 |
| Yes | 10 (7.1%) | 13 (9.3%) | 16 (11.4%) | 2 (1.4%) | 40 (28.6%) | 59 (42.1%) | 140 |
| HT | |||||||
| Negative | 63 (10.7%) | 50 (8.5%) | 52 (8.8%) | 4 (0.7%) | 149 (25.3%) | 272 (46.1%) | 590 |
| Positive | 17 (7.5%) | 24 (10.6%) | 28 (12.3%) | 2 (0.9%) | 73 (32.2%) | 83 (36.6%) | 227 |
| Surgery | |||||||
| Yes | 49 (6.8%) | 18 (2.5%) | 75 (10.4%) | 4 (0.6%) | 222 (30.7%) | 355 (43.5%) | 723 |
| No | 31 (33.0%) | 56 (59.6%) | 5 (5.3%) | 2 (2.1%) | 0 (0.0%) | 0 (0.0%) | 94 |
| Pathology or follow‐up US/US‐FNA | |||||||
| Benign | 50 (32.9%) | 67 (44.1%) | 24 (15.8%) | 4 (2.6%) | 4 (2.6%) | 3 (0.8%) | 152 |
| Malignant | 30 (4.5%) | 7 (1.1%) | 56 (8.4%) | 2 (0.3%) | 218 (32.8%) | 352 (52.9%) | 665 |
| Total | 80 (9.8%) | 74 (9.1%) | 80 (9.8%) | 6 (0.7%) | 222 (27.2%) | 355 (43.5%) | 817 |
US, ultrasound; ND/UNS, nondiagnostic/unsatisfactory; AUS/FLUS, atypia/follicular lesion of undetermined significance; FN/SFN, follicular neoplasm/suspicious for follicular neoplasm; SM, suspicious for malignancy; HT, Hashimoto's disease; US‐FNA, ultrasound‐guided fine‐needle aspiration.
Figure 2Correlations of presence of Hashimoto's thyroiditis (HT) with cytological and pathological results. (A) The positive rates of HT in ND/UNS, benign, AUS/FLUS, FN/SFN, SM, and malignant groups were, respectively, 21.2% (17/80), 32.4% (24/74), 35.0% (28/80), 33.3% (2/6), 32.9% (73/222), and 23.4% (83/355), (B) The HT‐positive rate between the ND/UNS group (21.2%) and the diagnostic group (28.5%) showed no significant difference (P = 0.170). (C) The concurrence rate of HT in indeterminate nodules (103/308, 33.4%) was significantly higher than in determinate nodules (107/429, 24.9%, P = 0.012). (D) The coexistent rate of HT showed no significant difference (P = 0.516) between benign (25.7%) and malignant (28.3%) nodules confirmed by pathology.
A comparison between HT‐positive subcentimeter nodules and HT‐negative nodules in diagnostic value of US‐FNA
| HT | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | FPR (%) | FNR (%) | AUC (95%CI) |
|
|---|---|---|---|---|---|---|---|---|
| Positive ( | 96.8% | 86.4% | 98.1% | 79.1% | 13.6% | 3.2% | 0.916 (0.83–1.00) |
|
| Negative ( | 99.5% | 92.3% | 99.0% | 96.0% | 7.7% | 0.5% | 0.959 (0.92–1.00) | |
| Total ( | 98.8% | 90.5% | 98.8% | 90.5% | 9.5% | 1.2% | 0.947 (0.91–0.99) |
Italic and bold type indicates statistical significance.
HT, Hashimoto's thyroiditis; US‐FNA, ultrasound‐guided fine‐needle aspiration; PPV, positive predictive value; NPV, negative predictive value; FPR, false‐positive rate; FNR, false‐negative rate; AUC, area under ROC curve; ROC, receiver operating curve; CI, confidence interval.
[Correction added on 19 April 2017, after first online publication: There are several changes in Table 2. The value in FPR (%) and FNR (%) column were previously wrong and these have now been corrected in this version.]
Univariate analysis of risk factors for false‐negative results of FNA in subcentimeter nodules
| Variables | Univariate analysis | ||
|---|---|---|---|
|
| OR | 95.0% CI for OR | |
| Female | 0.710 | 1.497 | 0.178–12.556 |
| Age ≥45 | 0.407 | 1.894 | 0.419–8.554 |
| US features | |||
| Nodule size < 0.5 cm | 0.629 | 1.503 | 0.288–7.845 |
| Isoechogenicity | 0.057 | 8.485 | 0.941–76.537 |
| Macrocalcification | 0.895 | 1.155 | 0.137–9.733 |
| Intranodular vascularity | 0.102 | 3.534 | 0.778–16.029 |
| HT |
| 6.830 | 1.311–35.573 |
Italic and bold type indicates statistical significance.
FNA, fine‐needle aspiration; OR, odds ratio; CI, confidence interval; US, ultrasound; HT, Hashimoto's thyroiditis.
Clinicopathological factors associated with indeterminate results of US‐FNA in subcentimeter nodules
| Variables |
| Indeterminate |
| |
|---|---|---|---|---|
| Negative | Positive | |||
| Gender | 0.860 | |||
| Female | 598 | 349 (58.4%) | 249 (41.6%) | |
| Male | 139 | 80 (57.6%) | 59 (42.4%) | |
| Age (years) | 737 | 45.45 ± 11.23 | 46.76 ± 11.53 | 0.120 |
| US features | ||||
| Nodule size (cm) |
| |||
| <0.5 | 140 | 68 (48.6%) | 72 (51.4%) | |
| ≥0.5 | 597 | 361 (60.5%) | 236 (39.5%) | |
| Echogenicity | 0.730 | |||
| Hypoechogenicity | 716 | 416 (58.1%) | 300 (41.9%) | |
| Isoechogenicity | 21 | 13 (61.9%) | 8 (38.1%) | |
| Calcification |
| |||
| None/Microcalcification | 637 | 380 (59.7%) | 257 (40.3%) | |
| Macrocalcification | 100 | 49 (49.0%) | 51 (51.0%) | |
| Intranodular vascularity | 0.472 | |||
| No | 607 | 357 (58.8%) | 250 (41.2%) | |
| Yes | 130 | 72 (55.4%) | 58 (44.6%) | |
| HT |
| |||
| Absent | 527 | 322 (61.1%) | 205 (38.9%) | |
| Present | 210 | 107 (51.0%) | 103 (49.0%) | |
Italic and bold type indicates statistical significance.
US‐FNA, ultrasound‐guided fine‐needle aspiration; OR, odds ratio; CI, confidence interval; US, ultrasound; HT, Hashimoto's thyroiditis.
Logistic regression analysis for risk factors of indeterminate results of US‐FNA
| Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
|
| OR | 95.0% CI for OR |
| OR | 95.0% CI for OR | |
| Female | 0.862 | 0.967 | 0.666–1.406 | |||
| Age | 0.123 | 1.010 | 0.997–1.023 | |||
| US features | ||||||
| Nodule size < 0.5 cm |
| 1.620 | 1.119–2.344 |
| 1.717 | 1.179–2.500 |
| Isoechogenicity | 0.728 | 0.853 | 0.349–2.085 | |||
| Macrocalcification |
| 1.539 | 1.008–2.349 |
| 1.749 | 1.136–2.692 |
| Intranodular vascularity | 0.472 | 1.150 | 0.785–1.685 | |||
| HT |
| 1.512 | 1.095–2.087 |
| 1.573 | 1.134–2.180 |
Italic and bold type indicates statistical significance.
US‐FNA, ultrasound‐guided fine‐needle aspiration; OR, odds ratio; CI, confidence interval; US, ultrasound; HT, Hashimoto's thyroiditis.